MiNK Therapeutics, Inc. (INKT) earnings
INKT earnings moved a median of -1.27% by the close. Quarterly and annual INKT reports and results, each read against the price at its own news timestamp. Back to the INKT overview →
30 measured INKT earnings events.
Where these INKT earnings landedvs 30 measured INKT earnings reactions
| Middle 50% of INKT earnings reactions | -4.85% to +1.40% |
|---|---|
| Median reaction (to close) | -1.27% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 INKT earnings events with a measured close landed between -4.85% and +1.40%; 30% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +1.53% | |
| MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury | Press release | +0.00% | -2.57% | |
| MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates | Press release | +0.00% | -5.98% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -3.65% | |
| MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation | Press release | -1.44% | -3.34% | |
| MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs | Press release | +0.00% | -0.55% | |
| Form 10-K MiNK Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -10.09% | -10.20% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.05% | -6.98% | |
| MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | Press release | -2.65% | -1.92% | |
| MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | Press release | -1.39% | +1.00% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.09% | -14.75% | |
| MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | Press release | +12.52% | +16.95% | |
| MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | Press release | +0.12% | -5.25% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | +5.46% | |
| MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress | Press release | +1.40% | -8.77% | |
| MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | Press release | — | +4.16% | |
| Form 10-K MiNK Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | — | -1.00% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -3.07% | |
| MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update | Press release | -0.25% | -6.25% | |
| MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report | Press release | -1.18% | -1.32% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -3.63% | |
| MiNK Reports Second Quarter 2024 Results and Business Update | Press release | -2.34% | -1.22% | |
| MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report | Press release | +0.00% | -0.22% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.99% | +10.89% | |
| MiNK Reports First Quarter 2024 Results | Press release | -0.99% | +10.89% | |
| MiNK to Provide Corporate Update and First Quarter 2024 Financial Report | Press release | -1.01% | +0.00% | |
| Form 10-K MiNK Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.12% | |
| Form 10-Q MiNK Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +2.25% | |
| MiNK Therapeutics Reports Third Quarter 2023 Results | Press release | -2.31% | -7.50% | |
| MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update | Press release | -4.22% | +4.25% |
Keep exploring
More INKT: analyst actions → · SEC filings → · INKT overview →